We looked for mutations in the Plasmodium falciparum K13 propeller gene of an artemisinin-resistant parasite on islands in Lake Victoria, Kenya, where transmission in 2012-2013 was high.The 4 new types of nonsynonymous, and 5 of synonymous, mutations we detected among 539 samples analyzed provide clues to understanding artemisinin-resistant parasites.T he worldwide spread of malaria parasites with resis- tance to antimalarial drugs has been a serious concern over the past few decades.During the 2000s, Plasmodium falciparum parasites acquired resistance to key drugs, such as chloroquine and sulfadoxine-pyrimethamine, in many malaria-endemic countries, including Kenya (1).Artemisinin-based combination therapy (ACT) has been introduced in most malaria-endemic countries and is the first-line therapy.However, the first clinical cases of artemisinin resistance in western Cambodia were reported in 2008 (2), and P. falciparum with reduced in vivo susceptibility to artesunate in western Cambodia was reported in 2009 (3,4).On the basis of these findings, genome-wide analyses of artemisinin-resistant P. falciparum isolates found strong correlations between a mutant allele in the K13 propeller, in vitro parasite survival rates, and in vivo parasite clearance rates; these correlations indicate that mutations in the K13 propeller (especially C580Y, R539T, and Y439H) are important determinants of artemisinin resistance (5,6).Analysis of parasites from several Cambodian provinces indicated that K13 propeller mutations are rarely observed in samples from provinces without documented resistance but are prevalent in provinces with reported resistance (6,7).In Kenya, ACT was introduced as first-line therapy for P. falciparum malaria in 2004 (1).However, various types of antimalarial drugs-including chroloquine, sulfadoxine-pyrimethamine, and artemether/lumefantrine-are available for purchase at pharmacies without physicians' prescriptions.In this study, we describe some K13 propeller mutations of P. falciparum parasites from western Kenya. The StudyThe research was conducted at 4 islands on Lake Victoria (Kibuogi, Ngodhe, Takawiri, Mfangano) and 1 shoreline community of Mbita District (Ungoye) in western Kenya (Figure).In this area, the PfPR 2-10 (community P. falciparum parasite rate standardized to the 2-to 10year age group) was reported in 2009 to be >40% (8).Although in some area of Kenya malaria has decreased, its prevalence remains high in the Lake Victoria basin because of the lake environment (8-10).In 2009, a total of 50%-70% of households owned insecticide-treated bed nets (11), which substantially reduce the risk for transmission of malaria parasites by providing barriers against mosquitoes.Although malaria is annually more prevalent in the 2 wet seasons (March-June and October-November) (9), in the study sites, it is highly endemic throughout the year.Filter paper blood spots were collected from participants (online Technical Appendix Table 1, http://wwwnc.cdc.gov/EID/article/21/3/14-0898-Techapp1.pdf) during populationwide cross-sectional malaria surveys conducted in February and August 2012 and August 2013 at the 5 study sites.We obtained ethics approval from the Kenyatta National Hospital and the University of Nairobi.All study participants provided informed consent.Parasitic DNA was extracted from the filter paper (12), and P. falciparum DNA was detected by a mitochondrial DNA-based PCR (13).Sequencing of the K13 propeller gene was attempted on the diagnostic PCR-positive specimens (online Technical Appendix).The prevalence of P. falciparum, as determined by PCR, in the rainy and dry seasons was 7.2%-26.2%and 6.5%-15.5% on the 3 small islands (Kibuogi, Ngodhe, and Takawiri), 47.3% and 31.4% on Mfangano Island, and 38.4% and 41.9%-64.0% in Ungoye, respectively (Table 1).We successfully analyzed 539 samples for the K13 propeller gene.Nine new types of point mutations were identified among these samples (Table 2).Participants infected with parasites harboring a mutation on the K13 propeller gene are listed in online Technical Appendix Table 2.The sequences reported in this study have been deposited in the DDBJ/EMBL/GenBank databases (accession nos.AB936059-AB936067).
No takes yet. Share an insight, caveat, or question.
Isozumi et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: